These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37638400)

  • 41. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
    Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
    J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Trinka E; Altamura C; Del Giovane C; Silvestrini M; Brigo F; Vernieri F
    Neurol Ther; 2022 Sep; 11(3):1235-1252. PubMed ID: 35705886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atogepant (Qulipta®) for migraine prevention.
    Hay DL; Walker CS; Harris PWR
    Trends Pharmacol Sci; 2022 Aug; 43(8):701-702. PubMed ID: 35469689
    [No Abstract]   [Full Text] [Related]  

  • 45. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.
    Houts CR; Wirth RJ; McGinley JS; Cady R; Lipton RB
    Headache; 2020 Oct; 60(9):2003-2013. PubMed ID: 32862469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.
    Dahlöf C; Loder E; Diamond M; Rupnow M; Papadopoulos G; Mao L
    Health Qual Life Outcomes; 2007 Oct; 5():56. PubMed ID: 17916258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study.
    Shibata M; Nakamura T; Ozeki A; Ueda K; Nichols RM
    J Pain Res; 2020; 13():3531-3538. PubMed ID: 33408512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topiramate improves health-related quality of life when used to prevent migraine.
    Diamond M; Dahlöf C; Papadopoulos G; Neto W; Wu SC
    Headache; 2005 Sep; 45(8):1023-30. PubMed ID: 16109116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
    Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
    Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF
    J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
    Kawata AK; Ladd MK; Lipton RB; Buse DC; Bensink M; Shah S; Hareendran A; Mannix S; Mikol D
    Headache; 2022 Feb; 62(2):159-168. PubMed ID: 35137394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atogepant for the prevention of episodic migraine in adults.
    Switzer MP; Robinson JE; Joyner KR; Morgan KW
    SAGE Open Med; 2022; 10():20503121221128688. PubMed ID: 36226229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
    Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
    Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.